Live Microbiota Therapy Prevents Recurrent CDI in Older Adul

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Related Keywords

Canada , Vancouver , British Columbia , Andrew Skinner , Cirlea Warren , American College Of Gastroenterology , Loyola University , University Of Virginia , American College , Scientific Meeting , Fecal Microbiota , Older Participants With Recurrent Clostridioides , Underlying Comorbidities , First Live Microbiota Treatment , Microbiome Based Therapies , Treating Recurrent , Spreferring , Rcdi , C Difficile , Recurrent , Microbiota , Acg 2023 , Data , Phase 3 ,